Literature DB >> 24224654

Identification of potent and selective cathepsin S inhibitors containing different central cyclic scaffolds.

Hans Hilpert1, Harald Mauser, Roland Humm, Lilli Anselm, Holger Kuehne, Guido Hartmann, Sabine Gruener, David W Banner, Joerg Benz, Bernard Gsell, Andreas Kuglstatter, Martine Stihle, Ralf Thoma, Rubén Alvarez Sanchez, Hans Iding, Beat Wirz, Wolfgang Haap.   

Abstract

Starting from the weakly active dual CatS/K inhibitor 5, structure-based design supported by X-ray analysis led to the discovery of the potent and selective (>50,000-fold vs CatK) cyclopentane derivative 22 by exploiting specific ligand-receptor interactions in the S2 pocket of CatS. Changing the central cyclopentane scaffold to the analogous pyrrolidine derivative 57 decreased the enzyme as well as the cell-based activity significantly by 24- and 69-fold, respectively. The most promising scaffold identified was the readily accessible proline derivative (e.g., 79). This compound, with an appealing ligand efficiency (LE) of 0.47, included additional structural modifications binding in the S1 and S3 pockets of CatS, leading to favorable in vitro and in vivo properties. Compound 79 reduced IL-2 production in a transgenic DO10.11 mouse model of antigen presentation in a dose-dependent manner with an ED50 of 5 mg/kg.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24224654     DOI: 10.1021/jm401528k

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  6 in total

1.  Lowering Lipophilicity by Adding Carbon: AzaSpiroHeptanes, a logD Lowering Twist.

Authors:  Sébastien L Degorce; Michael S Bodnarchuk; James S Scott
Journal:  ACS Med Chem Lett       Date:  2019-07-18       Impact factor: 4.345

Review 2.  Manipulating autophagic processes in autoimmune diseases: a special focus on modulating chaperone-mediated autophagy, an emerging therapeutic target.

Authors:  Fengjuan Wang; Sylviane Muller
Journal:  Front Immunol       Date:  2015-05-19       Impact factor: 7.561

Review 3.  Novel Opportunities for Cathepsin S Inhibitors in Cancer Immunotherapy by Nanocarrier-Mediated Delivery.

Authors:  Natalie Fuchs; Mergim Meta; Detlef Schuppan; Lutz Nuhn; Tanja Schirmeister
Journal:  Cells       Date:  2020-09-02       Impact factor: 6.600

Review 4.  Cathepsin S As an Inhibitor of Cardiovascular Inflammation and Calcification in Chronic Kidney Disease.

Authors:  Brena F Sena; Jose Luiz Figueiredo; Elena Aikawa
Journal:  Front Cardiovasc Med       Date:  2018-01-05

5.  Pharmacodynamic Monitoring of RO5459072, a Small Molecule Inhibitor of Cathepsin S.

Authors:  Michel Theron; Darren Bentley; Sandra Nagel; Marianne Manchester; Michael Gerg; Thomas Schindler; Ana Silva; Barbara Ecabert; Priscila Teixeira; Camille Perret; Bernhard Reis
Journal:  Front Immunol       Date:  2017-07-17       Impact factor: 7.561

6.  Characterization of Covalent-Reversible EGFR Inhibitors.

Authors:  Steven Smith; Marina Keul; Julian Engel; Debjit Basu; Simone Eppmann; Daniel Rauh
Journal:  ACS Omega       Date:  2017-04-20
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.